Sellas Announces Positive Data from Phase 2a Trial of SLS009
SELLAS Life Sciences announced positive Phase 2a trial data for SLS009 (tambiciclib), a CDK9 inhibitor, combined with Brukinsa (zanubrutinib)...
PolarityBio Receives Breakthrough Therapy Designation for Treatment of Wagner Grade I Diabetic Foot Ulcers
PolarityBio’s SkinTE received Breakthrough Therapy Designation from the FDA for treating Wagner Grade 1 Diabetic Foot Ulcers (DFUs). This...
Promising Aquadex Therapy for Heart Failure: Updated AVOID-HF Study Analysis
Nuwellis, Inc. announced updated findings from the AVOID-HF study, published in the Journal of the American College of Cardiology:...
Vaxxas HD-MAP Vaccine Delivery Clinical Trial Sets Record
Vaxxas, a clinical-stage biotech company, has completed enrollment for its Phase I clinical trial of an avian influenza A...
DeepSon Bio at Korean Society of Brain Neuromodulation Therapy
Professor Kim Jae-ho presented positive findings from an exploratory clinical trial using Deepson Bio’s NEUCLARE therapeutic ultrasound device to...
Innocare Announces BCL2 Inhibitor & Orelabrutinib for CLL/SLL
InnoCare Pharma received approval from China’s CDE to begin a Phase III trial of its BCL2 inhibitor, ICP-248 (Mesutoclax),...
GSK’s PENMENVY Vaccine Approved by US FDA
The FDA approved GSK’s PENMENVY, a combination vaccine against five serogroups of meningococcal disease (A, B, C, W, and...
Revolutionary New Prostate Cancer Super Test Developed in UK
Scientists in Cambridge developed a new prostate cancer test designed to revolutionize screening, diagnosis, and personalized treatment. The test...
Lacutamab Gets FDA Breakthrough Therapy for Sézary Syndrome
Innate Pharma received Breakthrough Therapy Designation from the FDA for lacutamab, its anti-KIR3DL2 antibody, for treating relapsed or refractory...
Carmat Aeson® Artificial Heart Shows Promise for Pulmonary Hypertension Patients
A single-center study at the University Medical Center of Astana, Kazakhstan, demonstrated the effectiveness of the Aeson® total artificial...